Edging toward New Therapeutics with Cyclin D1 Egl'ng on Cancer

Chi V. Dang

Research output: Contribution to journalArticle

Abstract

In this issue of Cancer Cell, Zhang et al. reports that the iron-dependent 2-oxoglutarate dioxygenase or prolyl hydroxylase EglN2 induces Cyclin D1 levels, egging on breast tumorigenesis. Their observations through loss of function studies suggest the potential for drug-like molecules inhibiting EglN to serve as new cancer therapeutics.

Original languageEnglish (US)
Pages (from-to)361-362
Number of pages2
JournalCancer Cell
Volume16
Issue number5
DOIs
StatePublished - Nov 6 2009

Fingerprint

Cyclin D1
Prolyl Hydroxylases
Dioxygenases
Neoplasms
Carcinogenesis
Breast
Iron
Therapeutics
Pharmaceutical Preparations
alpha-ketoglutaric acid

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

Edging toward New Therapeutics with Cyclin D1 Egl'ng on Cancer. / Dang, Chi V.

In: Cancer Cell, Vol. 16, No. 5, 06.11.2009, p. 361-362.

Research output: Contribution to journalArticle

Dang, Chi V. / Edging toward New Therapeutics with Cyclin D1 Egl'ng on Cancer. In: Cancer Cell. 2009 ; Vol. 16, No. 5. pp. 361-362.
@article{1bb0c02c607d4469bfc08c31ce4fadbf,
title = "Edging toward New Therapeutics with Cyclin D1 Egl'ng on Cancer",
abstract = "In this issue of Cancer Cell, Zhang et al. reports that the iron-dependent 2-oxoglutarate dioxygenase or prolyl hydroxylase EglN2 induces Cyclin D1 levels, egging on breast tumorigenesis. Their observations through loss of function studies suggest the potential for drug-like molecules inhibiting EglN to serve as new cancer therapeutics.",
author = "Dang, {Chi V.}",
year = "2009",
month = "11",
day = "6",
doi = "10.1016/j.ccr.2009.10.001",
language = "English (US)",
volume = "16",
pages = "361--362",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "5",

}

TY - JOUR

T1 - Edging toward New Therapeutics with Cyclin D1 Egl'ng on Cancer

AU - Dang, Chi V.

PY - 2009/11/6

Y1 - 2009/11/6

N2 - In this issue of Cancer Cell, Zhang et al. reports that the iron-dependent 2-oxoglutarate dioxygenase or prolyl hydroxylase EglN2 induces Cyclin D1 levels, egging on breast tumorigenesis. Their observations through loss of function studies suggest the potential for drug-like molecules inhibiting EglN to serve as new cancer therapeutics.

AB - In this issue of Cancer Cell, Zhang et al. reports that the iron-dependent 2-oxoglutarate dioxygenase or prolyl hydroxylase EglN2 induces Cyclin D1 levels, egging on breast tumorigenesis. Their observations through loss of function studies suggest the potential for drug-like molecules inhibiting EglN to serve as new cancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=70350492579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350492579&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2009.10.001

DO - 10.1016/j.ccr.2009.10.001

M3 - Article

C2 - 19878865

AN - SCOPUS:70350492579

VL - 16

SP - 361

EP - 362

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 5

ER -